Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

Similar articles for PubMed (Select 24436439)

1.

Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.

Kim SM, Woo JS, Jeong CH, Ryu CH, Jang JD, Jeun SS.

Stem Cells Transl Med. 2014 Feb;3(2):172-82. doi: 10.5966/sctm.2013-0132. Epub 2014 Jan 16.

2.

Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.

Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS.

Cancer Res. 2012 Sep 15;72(18):4807-17. doi: 10.1158/0008-5472.CAN-12-0123. Epub 2012 Sep 7.

3.
4.

Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.

Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K.

Mol Cancer Ther. 2008 Nov;7(11):3575-85. doi: 10.1158/1535-7163.MCT-08-0640.

5.

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.

Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM.

Free Radic Biol Med. 2012 Jan 15;52(2):377-91. doi: 10.1016/j.freeradbiomed.2011.10.487. Epub 2011 Nov 3.

PMID:
22094224
6.

Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.

Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.

Neurosurgery. 2009 Sep;65(3):610-24; discussion 624. doi: 10.1227/01.NEU.0000350227.61132.A7.

PMID:
19687708
7.
8.

Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.

Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16. doi: 10.1016/j.ijrobp.2008.02.005.

9.

Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.

Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M, Oh W, Park SH, Sung YC, Jeun SS.

Cancer Res. 2008 Dec 1;68(23):9614-23. doi: 10.1158/0008-5472.CAN-08-0451.

10.

Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.

Yulyana Y, Endaya BB, Ng WH, Guo CM, Hui KM, Lam PY, Ho IA.

Stem Cells Dev. 2013 Jul 1;22(13):1870-82. doi: 10.1089/scd.2012.0529. Epub 2013 Mar 26.

11.
12.

Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.

Dong J, Zhou G, Tang D, Chen Y, Cui B, Dai X, Zhang J, Lan Q, Huang Q.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2079-84. doi: 10.1007/s00432-012-1290-3. Epub 2012 Jul 24.

PMID:
22825126
13.

Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma.

Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, Jung HW, Lee DH, Kim SK.

Neuro Oncol. 2011 Jan;13(1):61-9. doi: 10.1093/neuonc/noq147. Epub 2010 Nov 9.

14.

TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.

Zhuang D, Liu Y, Mao Y, Gao L, Zhang H, Luan S, Huang F, Li Q.

Int J Cancer. 2012 Jan 15;130(2):309-18. doi: 10.1002/ijc.25985. Epub 2011 May 30.

PMID:
21328340
15.

Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.

Liu XY, Zhang L, Wu J, Zhou L, Ren YJ, Yang WQ, Ming ZJ, Chen B, Wang J, Zhang Y, Yang JM.

PLoS One. 2013 Nov 26;8(11):e81345. doi: 10.1371/journal.pone.0081345. eCollection 2013.

16.

Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.

Gong A, Ge N, Yao W, Lu L, Liang H.

Cancer Chemother Pharmacol. 2014 Sep;74(3):531-8. doi: 10.1007/s00280-014-2534-5. Epub 2014 Jul 22.

PMID:
25047724
17.

Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.

Fukai J, Koizumi F, Nakao N.

PLoS One. 2014 Aug 11;9(8):e104538. doi: 10.1371/journal.pone.0104538. eCollection 2014.

18.

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.

Yu R, Deedigan L, Albarenque SM, Mohr A, Zwacka RM.

Cell Death Dis. 2013 Feb 21;4:e503. doi: 10.1038/cddis.2013.19.

19.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

PMID:
24093630
20.

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, Gillespie GY, Grizzle WE, Buchsbaum DJ, Kaliberov SA.

Cancer Gene Ther. 2009 Oct;16(10):794-805. doi: 10.1038/cgt.2009.23. Epub 2009 Apr 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk